[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"castlemans-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:castlemans-disease":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,46,57,97,124],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100053304","molecular-characterization-of-viral-associated-tumors-tumors-occurring-in-the-setting-of-hiv-or-other-immune-disorders-and-castleman-disease-100053304",false,"NCT03300830","Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease","* INCLUSION CRITERIA:\n\nParticipants with one or more of the following:\n\n* HIV or other acquired immunodeficiency and cancer\n* Viral-associated cancer or cancer hypothesized to be caused by a virus\n* HIV-negative participants with cancer that commonly occurs in people with HIV\n\n  --KSHV-associated malignancy or related diseases, such as Multicentric Castleman Disease (MCD)\n* A malignancy hypothesized to be caused by an endogenous retrovirus\n* Idiopathic Castleman disease\n\nCancer diagnoses will be confirmed by the NCI Laboratory of Pathology (LP). A biopsy will be collected if sufficient archival tissue is not available.\n\n* Age \\>=18 years.\n* ECOG performance status \\\u003C=2 (Karnofsky \\>=60%) if biopsy to be performed is solely for the purposes of this protocol. Any ECOG performance status will be allowed if biopsy required for participant care or another NIH protocol that allows lower performance status or if enrollment on this protocol is only for the purposes of studying tissue that has already been collected.\n* Participants must have signed or be willing to sign an IRB-approved informed consent document that permits the use of the tumor and other samples for genomic-based molecular characterization projects. Telephone consent for use of archival tissue or tissue collected on another protocol or standard participant care will be permitted.\n* Co-enrollment on other HAMB, NCI, or NIH protocols is allowed\n\nEXCLUSION CRITERIA:\n\n* Inability to provide informed consent.\n* Pregnancy: Pregnant women will not be allowed to participate in this study because there is not a potential benefit.","ALL","18 Years",{"count":18,"type":19},280,"ESTIMATED","OBSERVATIONAL","Background:\n\nA person s genome is the collection of all their genes. A gene instructs individual cells to make proteins. Proteins are involved in all of our body s chemical processes. Genome sequencing allows researchers to find variations in genes. Some of these are normal and are not known to cause disease. Some variants are known to cause or affect diseases like cancer. Researchers want to study genetic variants in people with cancer who also have an immunologic disease like HIV.\n\nObjective:\n\nTo study the biology of cancer in order to improve ways to prevent, detect, and treat it.\n\nEligibility:\n\nAdults at least 18 years old with certain cancers and\u002For immunodeficiencies\n\nDesign:\n\nParticipants will be screened with medical history, physical exam, and lab tests.\n\nParticipants will give samples of one or more tissue type.\n\nThey may give blood or urine samples.\n\nResearchers may get samples of tissue when participants have surgery or when the participants are on other protocols in the NCI.\n\nParticipants may have a procedure to have tissue samples removed.\n\nResearchers may collect data from participant medical records.\n\nResearchers will compare the genes in a participant s cancer tissue to their normal tissue. They may use the tissue cells to grow new cells in a lab.\n\nParticipants may be contacted about the results.\n\nThe samples will be stored for future research. No personal data will be kept with them.\n\n...",[23,24,25,26],"Human Immunodeficiency Virus","Castleman's Disease","Kaposi's Sarcoma","Viral-Associated Cancer",[28,26,29,30,31,32],"Immunodeficiency","Kaposi Sarcoma Herpes Virus","Idiopathic Castleman Disease","Endogenous Retroviruses","Natural History","RECRUITING","2026-07-10",{"date":36,"type":37},"2026-07-13","ACTUAL",{"date":39,"type":37},"2017-12-20",{"date":41,"type":19},"2037-06-25",{"name":43,"class":44},"National Cancer Institute (NCI)","NIH",1,{"id":47,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":49,"keywords":50,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":54,"completionDateStruct":55,"leadSponsor":56,"locationsCount":45},"100308862",{"count":18,"type":19},[23,24,25,26],[28,26,29,30,31,32],"2026-06-23",{"date":53,"type":37},"2026-06-24",{"date":39,"type":37},{"date":41,"type":19},{"name":43,"class":44},{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":65,"targetDuration":67,"studyType":20,"phases":4,"briefSummary":68,"conditions":69,"keywords":78,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":45},"100271815","international-registry-for-patients-with-castleman-disease-100271815","NCT02817997","International Registry for Patients With Castleman Disease","ACCELERATE (Advancing Castleman Care With an Electronic Longitudinal Registry, E-Repository, And Treatment\u002FEffectiveness Research): An International Registry for Patients With Castleman Disease","ACCELERATE","Inclusion Criteria:\n\n* Person of any age\n* Have a reference pathology report suggesting \"Castleman disease\" not limited to cutaneous involvement only that can be uploaded\n* Be able to provide electronic informed consent, as per local regulations\n* Deceased patients may also be enrolled when a reference pathology report suggesting \"Castleman disease\" can be supplied or when the ART is able to locate and upload such a pathology report.\n\nExclusion Criteria:\n\n* Because this registry is designed to provide as wide a picture of routine clinical practice as possible, inclusion criteria are set deliberately wide and there are no exclusion criteria.",{"count":66,"type":19},1000,"10 Years","The purpose of this study is to collect clinical, laboratory, and patient survey data from patients with Castleman disease to improve understanding, diagnosis, and treatment of the disease. Funding source - FDA OOPD.",[70,24,71,72,73,74,75,76,77],"Castleman Disease","Giant Lymph Node Hyperplasia","Angiofollicular Lymph Hyperplasia","Angiofollicular Lymph Node Hyperplasia","Angiofollicular Lymphoid Hyperplasia","GLNH","Hyperplasia, Giant Lymph Node","Lymph Node Hyperplasia, Giant",[79,80,81,82,83,84,24,72,85,86],"patient registry","ACCELERATE study","CD","MCD","iMCD","Castleman","multicentric Castleman's disease","multicentric Castleman disease","2026-02-27",{"date":89,"type":37},"2026-03-03",{"date":91,"type":4},"2016-10",{"date":93,"type":19},"2027-09",{"name":95,"class":96},"University of Pennsylvania","OTHER",{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":103,"targetDuration":67,"studyType":20,"phases":4,"briefSummary":105,"conditions":106,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":45},"100340846","registry-for-adults-with-plasma-cell-disorders-pcds-100340846","NCT03717844","Registry for Adults With Plasma Cell Disorders (PCD's)","Inclusion Criteria:\n\n* Patients have an outpatient appointment or are hospitalized inpatient at UNC Cancer Hospitals, or affiliated clinic settings or participating sites for the evaluation and management of a PCD.\n* Patients have a documented diagnosis of PCD defined as the presence of a monoclonal protein and\u002For monoclonal plasma cell population. Examples of PCDs include but are not limited to monoclonal gammopathy of uncertain significance; smoldering myeloma; multiple (active) myeloma; plasma cell leukemia; Castleman's disease; amyloidosis; light and\u002For heavy chain deposition disease; Polyneuropathy, Organomegaly, Endocrinopathy,Monoclonal gammopathy and Skin changes (POEMS) syndrome; and cryoglobulinemia.\n* Age ≥18 years.\n* Must consent to participation in this study and agree to complete the assessment at baseline and follow-up time points.\n* Must be able to read and speak English.\n\nExclusion Criteria:\n\n* Physical or psychiatric\u002Fbehavioral illnesses or problems that the treating clinician feels would preclude successful participation in the study.\n* There are no imaging or lab studies required to determine eligibility.",{"count":104,"type":19},2000,"The primary purpose of this protocol is to create a registry of patients with plasma cell disorders (PCDs), including for example the cancer multiple myeloma (MM), who complete the assessment, previously known as a \"geriatric assessment,\" as is outlined in this protocol. Secondary objectives include measuring the response rate to participation of patients in this study, assessing patient satisfaction with the questionnaire, and gathering information that would lend support for future research into these types of assessments in patients with PCDs. Additionally the study offers an optional blood draw to look at a genetic marker of aging called p16INK4a (IRB 15-1899, IRB 15-0244).",[107,108,109,24,110,111,112,113,114],"Multiple Myeloma","Amyloidosis","Cryoglobulinemia","Light Chain Deposition Disease","Heavy Chain Deposition Disease","Polyneuropathy Organomegaly Endocrinopathy Monoclonal Gammopathy and Skin Changes","Smoldering Multiple Myeloma","Plasma Cell Leukemia","2025-11-19",{"date":117,"type":37},"2025-11-20",{"date":119,"type":37},"2018-02-09",{"date":121,"type":19},"2029-02",{"name":123,"class":96},"UNC Lineberger Comprehensive Cancer Center",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":131,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":133,"conditions":134,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":45},"100461081","a-cohort-study-of-plasma-cell-disorders-pcds-in-pkufh-100461081","NCT05283993","A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH","A Prospective Cohort Study of Patients With Plasma Cell Disorders (PCDs) in PKUFH","Inclusion Criteria:\n\n1. Patients included are those with confirmed diagnosis of PCDs and hospitalized into Peking University First Hospital (PKUFH)\n2. Patients of plasma cell disorders (PCDs) are recruited. PCDs include monoclonal gammopathy of uncertain significance; smoldering myeloma; multiple myeloma; plasma cell leukemia; amyloidosis; light chain deposition disease; heavy chain deposition disease; Castleman's disease (CD); Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal gammopathy and Skin changes syndrome; cryoglobulinemia; Monoclonal Gammopathy of Renal Significance (MGRS); Monoclonal gammopathy of neurological significance (MGNS).\n3. Patients are included into this cohort after signing the ICFs.\n\nExclusion Criteria:\n\nSignificant comorbidity may be life-threatening.",true,{"count":104,"type":19},"The primary aim is to establish a prospective cohort of patients with plasma cell disorders (PCDs). All of the hospitalized PCD patients who are willing to sign the informed consent form (ICF) will be included in this study. Clinical characteristics, treatment options and responses will be collected. Peripheral blood, bone marrow aspirate and urine samples before and after the treatment will banked for future research. Our team will focus on the clinical and pathological features of PCDs, the correlation between the minimal residual disease (MRD) status and prognosis, and the role of Tumor Microenvironment (TME) in the pathogenesis and progress of PCDs.",[107,108,109,24,110,111,112,113,114,135,136,137],"Monoclonal Gammopathy of Undetermined Significance (MGUS)","Monoclonal Gammopathy of Renal Significance (MGRS)","Monoclonal Gammopathy of Neurological Significance (MGNS)","2022-04-21",{"date":140,"type":37},"2022-04-25",{"date":142,"type":37},"2021-07-01",{"date":144,"type":19},"2030-12-31",{"name":146,"class":96},"Peking University First Hospital"]